Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis

Blondon, Marc; Righini, Marc Philip; Bounameaux, Henri; Veenstra, David L

doi:10.1378/chest.11-0625

Scientific article

English

Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis

ContributorsBlondon, Marc

; Righini, Marc Philip

; Bounameaux, Henri; Veenstra, David L

Published inChest, vol. 141, no. 2, p. 321-329

Publication date2012

Abstract

According to the Comparison of Arixtra in Lower Limb Superficial Vein Thrombosis with Placebo (CALISTO) study, a recent randomized, controlled trial, prophylactic fondaparinux can prevent thrombotic complications following superficial vein thrombosis (SVT). The cost-effectiveness of this treatment remains to be determined.

Keywords

Anticoagulants/economics/therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Decision Trees
Female
Humans
Leg/blood supply
Male
Middle Aged
Polysaccharides/economics/therapeutic use
Quality-Adjusted Life Years
Venous Thrombosis/drug therapy

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Maladie thromboembolique veineuse (808)

Citation (ISO format)

BLONDON, Marc et al. Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. In: Chest, 2012, vol. 141, n° 2, p. 321–329. doi: 10.1378/chest.11-0625

Article (Published version)

Identifiers

PID : unige:23990
DOI : 10.1378/chest.11-0625
PMID : 21757569

Journal ISSN0012-3692

657views

0downloads

Creation11/10/2012 08:58:00

First validation11/10/2012 08:58:00

Update09/02/2026 14:33:32

Status update09/02/2026 14:33:32

Last indexation20/04/2026 15:27:05

Archive ouverte UNIGE

Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis

Technical informations